Magnetic resonance-guided focused ultrasound (MRgFUS) is a non-invasive technique for neuroregulation

The mechanism of MRI-guided focused ultrasound. Graphic courtesy of Haoxuan Lu, Yujue Zhong, et al.


April 8, 2024 — Magnetic resonance-guided focused ultrasound (MRgFUS) is a non-invasive technique for neuroregulation. It offers several advantages, including being non-invasive, eliminates the need for general anesthesia requirement, and enables real-time target localization and real-time temperature monitoring. Currently, the U.S. Food and Drug Administration has approved this technology for the treatment of essential tremor and Parkinson's disease, and its indications are expanding to include various intracranial diseases.

In a new review published in the KeAi journal Meta-Radiology, a team of researchers from the Chinese PLA General Hospital in China summarized the clinical trials of high-intensity FUS in the treatment of intracranial diseases. The team searched the PubMed, Embase, and Web of Science databases from January 1, 2013, to November 1, 2023, using the search terms: “MRgFUS,” or “MRI-guided Focused Ultrasound,” or “magnetic resonance imaging-guided focused ultrasound,” or “magnetic resonance-guided focused ultrasound.”

“According to the inclusion and exclusion criteria for initial literature screening, we identified several current intracranial applications of magnetic resonance-guided high-intensity focused ultrasound, which include “essential tremor,” "Parkinson's disease,” “obsessive compulsive disorder,” “major depressive disorder,” “neuropathic pain,” and “focal dystonia”,” shares corresponding author Xin Lou.

The review also introduces the preclinical and clinical studies on low-intensity FUS-induced blood-brain barrier opening and neuromodulation, and discusses the challenges and future directions of MRgFUS technology.

“We found that MRgFUS has emerged as a novel therapeutic approach in functional neurosurgery. High-intensity FUS is a safe and effective treatment for various intracranial diseases. Nonetheless, the neurobiological effects of low intensity FUS- blood–brain barrier opening and neuromodulation are not fully understood. Therefore, further preclinical and clinical studies are required to explore these effects. Neuroimaging is essential for localizing targets and exploring potential neurobiological effects in MRgFUS,” concludes Lou.

For more information: https://www.keaipublishing.com/


Related Content

News | X-Ray

Dec. 1, 2025 – Zwanger-Pesiri Radiology, one of the most respected and technologically advanced outpatient radiology ...

Time December 03, 2025
arrow
News | Interventional Radiology

Dec. 1, 2025 — GE HealthCare has unveiled the Allia Moveo,1 an image guiding solution designed to enhance mobility and ...

Time December 02, 2025
arrow
News | Archive Cloud Storage

Nov. 30, 2025 — Gradient Health, Inc. has released Atlas 2, a major upgrade to its self-service medical imaging data ...

Time December 01, 2025
arrow
News | Artificial Intelligence

Nov. 24, 2025 — Siemens Healthineers is launching artificial intelligence-enabled services to help healthcare providers ...

Time November 24, 2025
arrow
News | Artificial Intelligence

Nov. 20, 2025 — Aidoc has announced a collaboration with AdventHealth to launch one of the largest imaging AI ...

Time November 21, 2025
arrow
News | Advanced Visualization

Nov. 20, 2025 — Avatar Medical and Barco have launched Eonis Vision, marking a new evolution in how medical imaging is ...

Time November 20, 2025
arrow
News | Neuro Imaging

Nov. 19, 2025 — Royal Philips has announced an extended partnership with Cortechs.ai. Together, the companies will ...

Time November 19, 2025
arrow
News | Radiology Business

Nov. 13, 2025 — Covera Health recently announced that Advanced Radiology Services (ARS) has joined its national Quality ...

Time November 17, 2025
arrow
News | Radiology Business

Nov. 12, 2025 — Siemens has announced plans to deconsolidate its remaining stake in Siemens Healthineers (currently ...

Time November 13, 2025
arrow
News | Orthopedic Imaging

Nov.10, 2025 — Medical imaging technology company Adaptix Ltd. has received 510(k) clearance from the U.S. Food and Drug ...

Time November 11, 2025
arrow
Subscribe Now